Mantle Cell Lymphoma Treatment Market

Mantle Cell Lymphoma Treatment Market Outlook (2024 to 2034)

A new study by Fact.MR reveals that the global mantle cell lymphoma treatment market is forecasted to increase from a value of US$ 2.53 billion in 2024 to US$ 5.77 billion by the end of 2034. This increase will equate to market expansion at a CAGR of 8.6% from 2024 to 2034.

Mantle cell lymphoma (MCL) is a rare type of non-Hodgkin’s lymphoma that primarily affects older patients. Standard treatment involves chemotherapy followed by a transplant, but the lymphoma often comes back and is resistant to chemotherapy.

In recent years, targeted therapies have become highly important in treating MCL, focusing on disrupting the abnormal biological processes driving its development. These therapies target NF-kB activation, Bruton’s Tyrosine Kinase signaling, and anti-apoptosis. They are increasingly used in cases where the disease has returned or is resistant to treatment, as well as in initial treatment and combination with other medications.

Key Market Growth Drivers

• Advancements in targeted therapies, immunotherapy innovations, personalized medicine trends, global market expansion, and rising incidence rates are contributing to mantle cell lymphoma treatment market growth.
• Immunotherapy advancements, precision medicine, and biomarker development targeted therapies for specific pathways, combination therapies, and the integration of artificial intelligence (AI) are among the major trends expected during the forecast period.
• Increasing prevalence of mantle cell lymphoma is expected to drive the future growth of the mantle cell lymphoma therapeutics market. Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL), a cancer of the lymphatic system.
• The MCL treatment market is expected to evolve further as research and development progresses. As new therapies are being introduced and adopted, the mantle cell lymphoma treatment market size is projected to grow at a significant pace during the forecast period.
• Addressing the issues of cost, side effects, and resistance is critical to ensuring that patients have access to effective and affordable therapies.
• Improved diagnostic techniques and increased awareness among healthcare providers have resulted in more accurate and timely diagnoses of MCL, expanding the patient population eligible for new treatments.
• Advancements in genomics and molecular biology have made personalized treatment plans possible, increasing therapy efficacy and driving market demand.
• Ongoing research and clinical trials are resulting in the development of new and more effective treatments, which are eventually contributing to market growth.
• MCL treatments are becoming more widely available as healthcare infrastructure and access to services are improving in both developed and developing regions.

Report Attribute	Detail
Mantle Cell Lymphoma Treatment Market (2024E)	US$ 2.53 Billion
Forecasted Market Value (2034F)	US$ 5.77 Billion
Global Market Growth Rate (2024 to 2034)	8.6% CAGR
East Asia Market Share (2024E)	13.2%
North America Market Share (2024)	40.8% CAGR
Sales from Hospitals (2024E)	US$ 950.4 Million
Key Companies Profiled	F.Hoffman La Roche Ltd.; Abbvie, Inc.; Kite Pharma, Inc.; Bayer AG; Bristol-Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; GlaxoSmithKline Plc; Amgen, Inc.; Gilead Sciences, Inc.; Johnson and Johnson; BeiGene; Beijing InnoCare Pharma Tech; Hutchison Medipharma; Acerta Pharma; AstraZeneca.

What is Benefitting Providers of Mantle Cell Lymphoma Treatment?

“Proliferation of Telemedicine Services Enhancing Accessibility, Efficiency, and Patient Engagement”

Expansion of telemedicine services is a key mantle cell lymphoma treatment market trend. Telemedicine involves the remote delivery of healthcare services and medical consultations through telecommunications technology. The rise in telemedicine enhances accessibility, efficiency, and patient engagement in the mantle cell lymphoma therapeutics market, leading to improved overall care and treatment outcomes.

• For instance, a report published by the Centers for Disease Control and Prevention (CDC) in October 2022 revealed that 37% of adults in the United States used telemedicine services within the past 12 months in 2021. Notably, women (42%) were more likely to use telemedicine compared to men (31.7%).
• Telemedicine usage showed a positive correlation with age, with higher usage rates among older adults. Specifically, the rate increased from 29.4% among adults aged 18–29 to 43.3% among those aged 65 and above. Thus, the growth in telemedicine services is contributing to the expansion of the market.

What Challenges Do Mantle Cell Lymphoma Treatment Providers Need to Overcome?

“Limited Availability of Advanced Treatment Options and High Therapy Cost”

Some of the factors limiting the market for mantle cell lymphoma treatment include the limited availability of advanced treatment options, high therapy costs, potential side effects, and challenges in diagnosing and predicting the disease. Innovative treatments, particularly novel targeted therapies and CAR-T cell therapies, have high costs. This is limiting access for some patients and presenting challenges in terms of reimbursement and healthcare budget constraints. While new therapies show promise, they frequently have side effects that can impair patients’ quality of life.

Resistance to existing therapies and the risk of relapse are ongoing concerns. Addressing these issues necessitates ongoing research and the development of novel treatment approaches. The market for mantle cell lymphoma is fragmented, with different treatment guidelines and practices across regions, complicating the global market landscape and influencing market dynamics.

Country-wise Insights

North America is expected to hold 40.8% of the global mantle cell lymphoma treatment market share in 2024, followed by Western Europe which is estimated to account for 21.1%. Meanwhile, East Asia is poised to account for a 13.2% market share in 2024. Clinical trials are critical for improving cancer treatment, particularly in highly lethal cancers such as mantle cell lymphoma. Major cancer organizations, including the National Comprehensive Cancer Network, the American Society of Clinical Oncology, and the Association of Community Cancer Centers, believe that all cancer patients should be allowed to participate in clinical trials.

Why is the United States a Lucrative Market for MCL Treatment Providers?

“Robust Healthcare Infrastructure and Continuous Innovation in Therapeutic Approaches”

Attribute	United States
Market Value (2024E)	US$ 899.1 Million
Growth Rate (2024 to 2034)	7.7% CAGR
Projected Value (2034F)	US$ 1.89 Billion

Mantle cell lymphoma treatment is gaining prominence in the United States. The country is at the forefront of the global market for mantle cell lymphoma treatment due to its robust research infrastructure, continuous innovation in therapeutic approaches, widespread access to state-of-the-art medical technologies, and the extensive scope of clinical trials carried out within the country.

Presence of world-renowned medical institutions, acclaimed oncologists, and collaborative efforts between academic and industrial sectors have all bolstered the United States' position as a leader in advancing treatment options for mantle cell lymphoma worldwide.

How is the Market for Mantle Cell Lymphoma Treatment Faring in India?

“Government Push for Digitalization and Adoption of Advanced Medical Technologies”

Attribute	India
Market Value (2024E)	US$ 127.9 Million
Growth Rate (2024 to 2034)	14.6% CAGR
Projected Value (2034F)	US$ 498.9 Million

The market for mantle cell lymphoma treatment is expanding at a significant pace in India as the disease's prevalence increases and healthcare providers and patients are becoming more aware of it. The introduction of new drugs and therapies is expected to accelerate market growth. Regulatory bodies such as the Central Drugs Standard Control Organization (CDSCO) oversee drug approvals and ensure the availability of new therapies.

Recent targeted therapy and immunotherapy approvals have an impact on market dynamics. Improved healthcare infrastructure and access to advanced treatment facilities in major urban centers are primarily contributing to market growth. The cost remains a significant factor in the adoption of new therapies. Availability of generics and biosimilars is also influencing treatment choices.

Category-wise Insights

The market for mantle cell lymphoma treatment is divided into four types of therapies: chemotherapy, monoclonal antibody therapy, targeted therapy, radiotherapy, and stem cell transplant. Targeted therapy is set to account for a significant share of 37.5% in 2024. In terms of end users, the market is segmented into hospitals, specialty clinics, oncology research centers, rehabilitation centers, and ambulatory surgical centers. Of all these end users, hospitals are poised to hold a share of 37.5% in 2024.

Why is Chemotherapy the Key Treatment Option for Mantle Cell Lymphoma?

“Development of Advanced Infusion Pumps and Automated Systems for Precise Drug Delivery”

Attribute	Chemotherapy
Segment Value (2024E)	US$ 714.8 Million
Growth Rate (2024 to 2034)	8.4% CAGR
Projected Value (2034F)	US$ 1.6 Billion

Chemotherapy is a treatment that employs drugs to target and destroy the body's rapidly dividing cells using potent chemicals. These drugs can be used alone or in combination to treat cancer, as cancer cells proliferate quickly. Chemotherapy products include pumps, cannulas, catheters, and other devices. Infusion pumps, for example, are attached to the patient and administer a controlled amount of medication into the bloodstream gradually.

Chemotherapy services cover a range of cancers, including blood cancer, throat cancer, lung cancer, ovarian cancer, and stomach cancer. This treatment involves various drug types such as alkylating agents, antimetabolites, anti-tumor antibiotics, topoisomerase inhibitors, and mitotic inhibitors, which can be administered orally or intravenously.

Which End User Generates Significant Revenue Streams?

“Hospitals Preferred for Their Advanced Infrastructure and Medical Expertise”

Attribute	Hospitals
Segment Value (2024E)	US$ 950.4 Million
Growth Rate (2024 to 2034)	8.9% CAGR
Projected Value (2034F)	US$ 2.24 Billion

Hospitals hold the largest share of mantle cell lymphoma treatment due to their advanced infrastructure and medical expertise, essential for diagnosing and managing complex conditions like mantle cell lymphoma. They are key centers for administering chemotherapy, stem cell transplants, and other sophisticated treatments required by patients.

As the primary care providers for cancer patients, hospitals offer comprehensive facilities and multidisciplinary care teams specializing in oncology. This ensures a coordinated treatment approach, with access to specialized oncologists, hematologists, and other essential professionals for effective management of mantle cell lymphoma.

Hospitals maintain partnerships with pharmaceutical companies and engage in clinical trials, providing patients with access to the latest treatments and therapies. They also deliver crucial supportive care services and resources for patients and their families, reinforcing their role as central hubs for mantle cell lymphoma treatment.

Competitive Landscape

Key players in the mantle cell lymphoma treatment industry are expected to evolve further as research and development activities progress. Companies are focusing on introducing innovative therapies. However, addressing the issues of cost, side effects, and resistance is critical to ensuring that patients have access to effective and affordable therapies.

• AstraZeneca's Calquence (acalabrutinib), a next-generation selective Bruton's tyrosine kinase (BTK) inhibitor, was conditionally approved in China in March 2023 for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This is Calquence's first approved indication in China.
• Loxo Lilly, Eli Lilly and Company's oncology unit, announced in January 2023 that the United States Food and Drug Administration (FDA) approved Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor.

Fact.MR provides detailed information about the price points of leading players in the mantle cell lymphoma treatment market positioned across the world, sales growth, production capacity, and technological advancements, in this new market report.

Segmentation of MCL Treatment Market Research

• By Therapy :

  • Chemotherapy
  • Monoclonal Antibody Therapy
  • Targeted Therapy
  • Radiotherapy
  • Stem Cell Transplant

• By Drug :

  • Zanubrutinib
  • Ibrutinib
  • Pirtobrutinib
  • NVG-111
  • Rituximab
  • Cyclophosphamide
  • Doxorubicin
  • Vincristine
  • Prednisone
  • Bendamustine
  • HMPL-760
  • Orelabrutinib
  • Loxo-338

• By Route of Administration :

  • Oral
  • Injectable

• By End User :

  • Hospitals
  • Specialty Clinics
  • Oncology Research Centers
  • Rehabilitation Centers
  • Ambulatory Surgical Centers

• By Patient Pool :

  • Pediatric
  • Adult
  • Geriatric

• By Region :

  • North America
  • Western Europe
  • Eastern Europe
  • Latin America
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa